Gamma-secretase modulator 1 is primarily investigated for its potential therapeutic applications in treating Alzheimer's disease. It works by modulating the activity of gamma-secretase, an enzyme involved in the production of amyloid-beta peptides. By altering the enzyme's function, it aims to reduce the formation of toxic amyloid-beta plaques, which are a hallmark of Alzheimer's pathology. This approach is considered an alternative to gamma-secretase inhibitors, as it seeks to minimize adverse effects while still targeting the amyloid pathway. Research is ongoing to evaluate its efficacy and safety in preclinical and clinical studies.